deutenzalutamide

Deutenzalutamide (HC-1119) is a novel, orally bioavailable, non-steroidal small molecule that acts as a second-generation androgen receptor antagonist. It is a deuterated derivative of enzalutamide in which the N-methyl group of enzalutamide is replaced by tri-deuterated methyl. This modification increases metabolic stability and drug exposure in vivo while reducing metabolite production and potentially improving safety and efficacy compared to the parent compound. Deutenzalutamide competitively inhibits androgen binding to the androgen receptor (AR), blocking AR signaling pathways, inducing apoptosis in prostate cancer cells, and reducing their proliferation. It has demonstrated antitumor activity in metastatic castration-resistant prostate cancer (mCRPC) as well as preclinical efficacy against AR-positive triple-negative breast cancer (TNBC). The drug was designed and developed by Sichuan HISCO Pharmaceutical Co., Ltd., with further development by Hinova Pharmaceuticals[1][2][3][4][5][6][8].

Other names

deutenzalutamideHC-1119HC1119HC 1119enzalutamide deuterated